一种草药治疗糖尿病心肌病的方法:莫林加,生和大揭幕
Kaushal Shah1, Manjiri Jalgaonkar1, Aditi Vyas2
1Department of Pharmacognosy, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V. M. Road, Vile Parle (W), Mumbai, Maharashtra, India.
Archives of physiology and biochemistry
|January 31, 2025
概括
这项研究表明,生,大和的多草药配方有效地对抗糖尿病心肌病. 治疗减少了有害的生物标志物,增加了有益的酶,保护了糖尿病大鼠的心脏健康.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 糖尿病学 糖尿病学
背景情况:
- 糖尿病与慢性炎症有关,导致心肌损伤,包括纤维化,亡和亡.
- 一些单独的草药,如Zingiber officinale (生),Allium sativum (大) 和Moringa oleifera在治疗糖尿病方面表现有前途.
- 糖尿病心肌病是一种严重的并发症,需要有效的治疗策略.
研究的目的:
- 研究一种多草药配方对糖尿病心肌病的保护作用.
- 评估结合草药治疗在减轻糖尿病引起的心脏并发症方面的疗效.
- 为了测试一种多草药混合物可以在糖尿病老鼠模型中预防心脏功能障碍的假设.
主要方法:
- 在Sprague Dawley大鼠中,使用链毒素 (55毫克/公斤) 诱导糖尿病.
- 一种多草药配方Zingiber officinale,Allium sativum和Moringa oleifera给糖尿病老鼠服用了8周.
- 评估了心脏损伤,氧化应激和血糖水平的生物化学标志物.
主要成果:
- 多草药配方显著降低了血糖,肌,血尿素和心脏酶 (CK-MB,LDH,AST,Troponin-I) 的水平.
- 氧化应激的关键标志物,NADPH氧化酶4和与Ras相关的C3毒素基质-1,通过治疗而减少.
- 抗氧化酶的活性显著增加,包括超氧化解酶,酶和谷氨.
结论:
- 多草药配方在糖尿病大鼠中显示出显著的心脏保护作用.
- 这种草药组合有效地减轻了糖尿病及其相关心肌病的进展.
- 这些发现支持这种多草药配方在治疗糖尿病并发症方面的治疗潜力.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
505
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
505
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
01:15Diabetes: Management and Pharmacotherapy
232
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
232
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
01:22Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
404
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
404